The Opioid Settlement Money Is Landing, Mostly Missing Harm Reduction — and Clinicians Should Know Where It Goes

The opioid settlements, totalling over $50 billion nationally, are the largest public health windfall of the decade. What the money is being spent on — and what it is being stripped to backfill general revenue — is shaping the U.S. overdose landscape for the next 15 years. Clinicians working with substance use patients need to know the answer in their state, because it determines what referral options actually exist.

The spending pattern in 2026

The Petrie-Flom analysis is blunt: states are spending settlement dollars heterogeneously and, in several cases, as effective general revenue. The 18% headline for addiction treatment is an average, meaning half of states spend less. The 2% to syringe service programs is the number that captures the underlying political reality — harm reduction remains the most clinically supported and least politically supported intervention category.

The xylazine problem has outpaced policy. Xylazine, a veterinary sedative, is now present in most illicit fentanyl supplies in the eastern U.S. and spreading westward. It produces skin necrosis at injection and sedation unresponsive to naloxone. Johns Hopkins and Rand analyses name three interventions as high-impact, low-cost: xylazine test strips, wound-care outreach kits, and co-location of care at harm reduction sites. Settlement fund allocation to these items is, by the authors' description, "minimal."

The stimulant crisis — methamphetamine and cocaine overdose deaths, often involving fentanyl contamination — is the third vector. People who use stimulants often lack opioid tolerance, which makes fentanyl contamination disproportionately fatal for them. Test strips and education targeted at stimulant users is an intervention category the opioid-centric settlement framework does not naturally fund.

Clinical implications

Three items are worth tracking locally. First: check your state's published allocation (if one exists) and your county health department's breakdown. This tells you what referral infrastructure exists for your substance-using patients — syringe services, low-threshold buprenorphine, contingency management, wound care.

Second: for patients who use stimulants, fentanyl contamination risk is now a standard conversation, not a niche one. Fentanyl test strips are widely available and legal in most states. Brief education on their use, strip sources, and proper interpretation is a harm reduction intervention that takes 90 seconds and can prevent a fatal overdose.

Third: xylazine-associated wounds are becoming an outpatient psychiatric-adjacent issue, because patients with necrotic lesions may avoid medical care and self-treat. If you work in SUD treatment or with patients injecting, visible wounds need explicit non-stigmatizing discussion and wound-care referral.